Reading this clinical breakthrough? See how real patients are applying these numbers in real life. Compare real-world patient outcomes, lab numbers, and doctor visit tips—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Gut, Labs & Supplements Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Gut, Labs & Supplements Space →
★ Breakthrough Medical Research • 15 Landmark Multi-Trial Guides • 6,255 Indexed Studies

Longevity, Cellular Aging, Vaccines & Preventive Medicine — Clinical Trial Breakdowns & PubMed Evidence

Long-term human survival cohorts and Phase 3 prevention trials covering UKPDS 34 / TAME Metformin AMPK longevity pathways, muscle protein synthesis across eight decades of life, and adult vaccine coadministration trials. Explore 811 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.

★ #1 Lead Breakthrough Study • NEJM SURMOUNT-1 (176 Weeks) N = 1,032 Adults • p < 0.001

Once-Weekly Tirzepatide Cuts Type 2 Diabetes Progression by 94% Over 3 Years—With a 22.9% Sustained Weight Reduction

The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).

Two biomedical scientists in white lab coats inside a sunlit medical research laboratory pipetting clinical assay samples and reviewing trial results
Inside the Clinical Evidence Lab: Our research desk audits 6,255 human trials from NEJM, The Lancet, JAMA, and NCBI PubMed—reporting true Absolute Risk Reduction (ARR) and sample sizes (N) without pharma spin.
3. All Indexed Clinical Studies (811)

Longevity, Aging & Prevention — Clinical Trials & Study Reports (811)

Page 2 of 28 • Sorted by Participant Sample Size (N)
Randomized Controlled Trial N = 455

Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703).

Among 455 randomized patients (median age, 59 years; 181 [40%] female) with median follow-up 20 months, the median PFS for high-dose vitamin D3 (n&#x2009;=&#x2009;228) was 11.8 months (95% CI, 10.3-13.3) vs 10.3 months (95% CI, 9.4-12.2) for standard-dose vitamin D3 (n&#x2009;=&#

JAMA • 2026-11-07 Read Study
Phase 3 Randomized Trial N = 337

Phase III Randomized Trial: Coronary artery calcification is not associated with survival in advanced gastric and gastroesophageal junction cancer: a secondary analysis of the EXPAND trial (N = 337)

CT-defined CAC scoring has no relevant prognostic impact in advanced gastric and gastroesophageal junction cancer undergoing first-line chemotherapy. The present study cannot confirm the promising results for CAC scoring in lung cancer patients.

Journal of cancer research and clinical oncology • 2026-11-03 Read Study
Randomized Controlled Trial N = 333

Randomized Controlled Trial: Firearm Injury Prevention Bystander Intervention for Adolescents in Shooting Sports: A Cluster Randomized Clinical Trial (N = 333)

A total of 61 sites from 28 states were randomized (32 to intervention and 29 to control); 50 sites (intervention, 26 sites of 250 youth; control, 24 sites of 174 youth) completed baseline data collection. Of 424 participants, the median (IQR) age was 14 (13-16) years; 226 were male (53.3%).

JAMA health forum • 2026-11-06 Read Study
Randomized Controlled Trial N = 250

High-Efficiency Particulate Air Filters to Prevent Winter Respiratory Infections in Care Homes: The AFRI-c Cluster Randomized Clinical Trial.

During the study period, 91 care homes were randomized, 47 to receive communal room filters, with 569 bedroom residents (median [IQR] age, 87 [81-92] years; 398 [70.0%] female), and 44 without communal room filters, with 589 residents without bedroom filters (median [IQR] age, 88

JAMA Intern Med • 2026-11-07 Read Study
Phase III Randomized Trial N = 212

Phase III Randomized Trial: Targeting Accelerated Aging in COPD: The AMICO (A Trial of Metformin In COpd) Trial Design (N = 212)

AMICO is the first randomized trial specifically designed to evaluate metformin as a gerotherapeutic and disease-modifying intervention in COPD. The study may provide novel evidence supporting geroscience-based approaches to slow disease progression and improve long-term outcomes in patients with COPD.

COPD • 2026-12-15 Read Study
Evidence Methodology, PubMed Verification & YMYL Standards

Frequently Asked Questions About dotMD Clinical Trial Breakdowns

Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.